Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)

Inclusion Criteria: 1. Histologically confirmed CD20-positive nodal or extranodal MZBCL 2. MZBCL patients who relapsed or progressed: * At least one and a maximum of four prior lines of chemotherapy * During or after the last chemotherapy or radiotherapy or * Without progression within 6 months of the last dose of rituximab-based regimen 3. Patients age ≥ 18 years 4. ECOG PS 0-2 5. At least one bidimensionally measurable disease 6. Adequate hematologic, renal, and hepatic functions 7. Women of child-bearing potential should use two appropriate methods of contraception during the study 8. Written informed consent Exclusion Criteria: 1. Not all of the above inclusion criteria are met. 2. Prior chemotherapy within 4 weeks or radiotherapy within 6 weeks 3. Corticosteroids during last 28 days except chronic administration of prednisolone at a dose of \< 20mg/day for indications other than lymphomas 4. Evidence of CNS involvement by lymphomas 5. Active HBV/HCV infections, known HIV infection 6. Prior diagnosis of cancers within 5 years, except cervical intraepithelial neoplasia type 1, localized non-melanoma skin cancer, or small differentiated thyroid cancer 7. Serious concurrent disease: 8. Patients who are pregnant or lactating